Shares of Organon (OGN, Financial) plunged approximately 13% in premarket trading after the company announced a significant cut in its quarterly dividend to $0.02 per share from $0.28. This decision comes as the Merck spinoff, focused on women's health and biosimilars, aims to revise its capital allocation goals to reduce debt. Organon plans to achieve a net leverage ratio below 4.0x by the end of the year. This announcement coincided with its Q1 2025 results, which exceeded earnings expectations but met revenue forecasts, reporting $1.7 billion in revenue.
https://www.gurufocus.com/news/2820227/morning-brew-organon-slashes-dividend-amid-earnings-surprises
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.